The last patient will enter the study on Aug. 16 and results will follow about a month after that, Fujifilm director Junji Okada said during a first-quarter earnings call.
The company will then work with Japanese regulators on submitting the drug for approval to treat COVID-19, he said.
(Reporting by Rocky Swift; Editing by Jan Harvey)